Acasti Pharma Inc is a Canada-based biopharmaceutical company. The Company is focused on the research, development and commercialization of prescription drugs using omega 3 fatty acids (OM3s) derived from krill oil. OM3s has clinical evidence of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia (HTG). The Company's drug candidate is CaPre, an OM3 phospholipid, which is being developed for the treatment of severe hypertriglyceridemia, a condition characterized by abnormally high levels of triglycerides in the bloodstream (over 500 mg/dL) (severe hypertriglyceridemia or severe HTG).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:ACST
- CUSIP: N/A
- Web: www.acastipharma.com
- Market Cap: $18.83 million
- Outstanding Shares: 14,712,000
- 50 Day Moving Avg: $1.30
- 200 Day Moving Avg: $1.29
- 52 Week Range: $1.11 - $3.09
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.0000
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.17 per share
- Price / Book: 1.18
- EBIDTA: ($6,190,000.00)
- Net Margins: -35,290.48%
- Return on Equity: -47.38%
- Return on Assets: -43.03%
- Debt-to-Equity Ratio: 0.06%
- Current Ratio: 4.55%
- Quick Ratio: 4.55%
- Average Volume: 23,976 shs.
- Beta: 1.22
- Short Ratio: 4.2
Frequently Asked Questions for Acasti Pharma (NASDAQ:ACST)
What is Acasti Pharma's stock symbol?
Acasti Pharma trades on the NASDAQ under the ticker symbol "ACST."
How were Acasti Pharma's earnings last quarter?
Acasti Pharma, Inc. (NASDAQ:ACST) posted its earnings results on Tuesday, January, 15th. The company reported ($0.02) EPS for the quarter. Acasti Pharma had a negative return on equity of 47.38% and a negative net margin of 35,290.48%. View Acasti Pharma's Earnings History.
Who are some of Acasti Pharma's key competitors?
Some companies that are related to Acasti Pharma include Evoke Pharma (EVOK), Neuralstem (CUR), Immune Pharmaceuticals (IMNP), Eyegate Pharmaceuticals (EYEG), Venture Life Group PLC (VLG), Galena Biopharma (GALE), Apricus Biosciences (APRI), Aegerion Pharmaceuticals (AEGR), Amryt Pharma PLC (FAST), CoLucid Pharmaceuticals (CLCD), Sagent Pharmaceuticals (SGNT), SkyePharma PLC (SKP), Theravance Biopharma (TBPHV), Valeant Pharmaceuticals Intl (BVF) and XenoPort (XNPT).
Who are Acasti Pharma's key executives?
Acasti Pharma's management team includes the folowing people:
- Roderick Noel Carter, Executive Chairman of the Board
- Janelle D'Alvise, President, Chief Executive Officer
- Linda O'Keefe, Chief Financial Officer
- Pierre Lemieux Ph.D., Chief Operating Officer
- Laurent Harvey, Vice President- Clinical and Non-Clinical Affairs
- Jean-Daniel Belanger, Secretary, Director- Corporate Affairs
- Valier Boivin, Independent Director
- Jean-Claude Debard, Independent Director
- Ronald Denis, Independent Director
- Pierre Fitzgibbon, Independent Director
How do I buy Acasti Pharma stock?
Shares of Acasti Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acasti Pharma's stock price today?
MarketBeat Community Rating for Acasti Pharma (NASDAQ ACST)MarketBeat's community ratings are surveys of what our community members think about Acasti Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Acasti Pharma stock can currently be purchased for approximately $1.38.
Consensus Ratings for Acasti Pharma (NASDAQ:ACST) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Acasti Pharma (NASDAQ:ACST)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Acasti Pharma (NASDAQ:ACST)Earnings History by Quarter for Acasti Pharma (NASDAQ ACST)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Acasti Pharma (NASDAQ:ACST)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Acasti Pharma (NASDAQ:ACST)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Acasti Pharma (NASDAQ:ACST)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Acasti Pharma (NASDAQ:ACST)
Latest Headlines for Acasti Pharma (NASDAQ:ACST)
Acasti Pharma (ACST) Chart for Thursday, July, 27, 2017